{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:36:22Z","timestamp":1794573382509,"version":"4.9.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>CAR-T cell therapy has proven to be a disruptive treatment in the hematology field, however, less than 50% of patients maintain long-term response and early predictors of outcome are still inconsistently defined. Here, we aimed to optimize the detection of CD19 CAR-T cells in blood and to identify phenotypic features as early biomarkers associated with toxicity and outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental design<\/jats:title><jats:p>In this study, monitoring by flow cytometry and digital PCR (dPCR), and immunophenotypic characterization of circulating CAR-T cells from 48 patients treated with Tisa-cel or Axi-cel was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Validation of the flow cytometry reagent for the detection of CAR-T cells in blood revealed CD19 protein conjugated with streptavidin as the optimal detection method. Kinetics of CAR-T cell expansion in blood confirmed median day of peak expansion at seven days post-infusion by both flow cytometry and digital PCR. Circulating CAR-T cells showed an activated, proliferative, and exhausted phenotype at the time of peak expansion. Patients with increased expansion showed more severe CRS and ICANs. Immunophenotypic characterization of CAR-T cells at the peak expansion identified the increased expression of co-inhibitory molecules PD1 and LAG3 and reduced levels of the cytotoxicity marker CD107a as predictors of a better long-term disease control. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data show the importance of CAR-T cells in vivo monitoring and identify the expression of PD1LAG3 and CD107a as early biomarkers of long-term disease control after CAR-T cell therapy. <\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1152498","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:29:32Z","timestamp":1681446572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies"],"prefix":"10.3389","volume":"14","author":[{"given":"Clara Beatriz","family":"Garc\u00eda-Calder\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Sierro-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzalba","family":"Sanoja-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mu\u00f1oz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ruiz-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Reyes","family":"Jimenez-Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Delgado-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gueda","family":"Molinos-Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Guijarro-Albaladejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Carrasco-Brocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Manuel","family":"Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Ra\u00fal","family":"Garc\u00eda-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bl\u00e1zquez-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Reguera-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Francisca","family":"Gonz\u00e1lez-Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Reinoso-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Caballero-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1709919\/SUPPL_FILE\/NEJMOA1709919_DISCLOSURES.PDF","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01128","article-title":"Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma","volume":"11","author":"Garc\u00eda-Guerrero","year":"2020","journal-title":"Front Immunol"},{"key":"B3","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume-title":"Blood","author":"Mueller","year":"2017"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBMT.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical trials: Immunotherapy clinical pharmacology of tisagenlecleucel in b-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMOA1804980\/SUPPL_FILE\/NEJMOA1804980_DISCLOSURES.PDF","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse Large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2018883421","article-title":"CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory b-cell non-Hodgkin lymphoma","volume":"134","author":"Sauter","year":"2019","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large b cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.02.003","article-title":"Optimized assessment of qPCR-based vector copy numbers as a safety parameter for GMP-grade CAR T cells and monitoring of frequency in patients","volume":"17","author":"Kunz","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with axicabtagene ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4014\/JMB.2009.09006","article-title":"Comparison of digital PCR and quantitative PCR with various SARS-CoV-2 primer-probe sets","volume":"31","author":"Park","year":"2021","journal-title":"J Microbiol Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113208","article-title":"Sensitivity and specificity of CD19.CAR-T cell detection by flow cytometry and PCR","volume":"10","author":"Schanda","year":"2021","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cyto.b.21880","article-title":"New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry","volume":"98","author":"Maryamchik","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0330\/85570\/AM\/RECEPTOR-AFFINITY-AND-EXTRACELLULAR-DOMAIN","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281339","article-title":"ATRA works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells","volume":"108","author":"Garc\u00eda-Guerrero","year":"2023","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1380764\/SUPPL_FILE\/KONI_A_1380764_SM7464.PDF","article-title":"Co-Stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"Oncoimmunology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/MT.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy","volume":"17","author":"Milone","year":"2009","journal-title":"vivo. Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/S41571-021-00530-Z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS12071970","article-title":"Accurate in-vivo quantification of CD19 CAR-T cells after treatment with axicabtagene ciloleucel (Axi-cel) and tisagenlecleucel (Tisa-cel) using digital PCR","volume":"12","author":"Badbaran","year":"2020","journal-title":"Cancers 2020 Vol 12 Page 1970"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830773","article-title":"Monitoring of circulating CAR T cells: Validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following tisagenlecleucel","volume":"13","author":"Peinelt","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12967-021-02925-Z\/FIGURES\/5","article-title":"Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients","volume":"19","author":"Haderbache","year":"2021","journal-title":"J Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020903","article-title":"Comparison of FACS and PCR for detection of BCMA-CAR-T cells","volume":"23","author":"Reichman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric b-ALL","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult b cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed b cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med 2020 26:10"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory b cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med 2022 28:9"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat Rev Immunol 2002 2:4"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.2636938100","article-title":"Antigen-driven effector CD8 T cell function regulated by T-bet","volume":"100","author":"Sullivan","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14225576","article-title":"Modeling patient-specific CAR-T cell dynamics: Multiphasic kinetics via phenotypic differentiation","volume":"14","author":"Paix\u00e3o","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large b cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial anti-CD19 CAR T cells affects In vivo expansion and disease response in patients with Large b-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658314","article-title":"Advanced flow cytometry assays for immune monitoring of CAR-T cell applications","volume":"12","author":"Blache","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large b-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T Cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040\/42478\/AM\/IDENTIFICATION-OF-PREDICTIVE-BIOMARKERS-FOR","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discovery"},{"key":"B44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2116133\/SUPPL_FILE\/NEJMOA2116133_DATA-SHARING.PDF","article-title":"Axicabtagene ciloleucel as second-line therapy for Large b-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"New Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.1058126\/BIBTEX","article-title":"Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity","volume":"13","author":"De Matteis","year":"2023","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.56875\/2589-0646.1024","article-title":"Chimeric antigen receptor T-cell therapies in lymphoma patients with central nervous system involvement","volume":"15","author":"Yi","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13174279\/S1","article-title":"Clinical and product features associated with outcome of dlbcl patients to cd19-targeted car t-cell therapy","volume":"13","author":"Lamure","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/S12276-021-00568-0","article-title":"Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion","volume":"53","author":"Seo","year":"2021","journal-title":"Exp Mol Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T Cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.748768\/BIBTEX","article-title":"Speed and location both matter: Antigen stimulus dynamics controls CAR-T cell response","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nat 2017 543:7643"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS11071140\/S1","article-title":"Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with b cell malignancies","volume":"11","author":"Beider","year":"2022","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/J.MAM.2006.08.005","article-title":"Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy","volume":"27","author":"Eskelinen","year":"2006","journal-title":"Mol Aspects Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELLIMM.2008.08.007","article-title":"Relationship between CD107a expression and cytotoxic activity","volume":"254","author":"Aktas","year":"2009","journal-title":"Cell Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation","volume":"281","author":"Betts","year":"2003","journal-title":"J Immunol Methods"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2012-08-453738","article-title":"LAMP1\/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity","volume":"121","author":"Krzewski","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1152498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:29:41Z","timestamp":1681446581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1152498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2023.1152498"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1152498","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2023.1152498.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2023.1152498.s002","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1152498"}}